FOCUSED ON WOMEN'S HEALTH and hormone-sensitive cancer for healthy aging worldwide

Discover our research

Our solution

A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.

Find out about Intrarosa™

Our goal as a Quebec company


Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.

Research and Development

Latest News

Read the news


November 6, 2019

Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.

Endoceutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2019

Québec City, Canada, April 25th, 2019; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.

Endoceutics, Université Laval, and CHU de Québec settle their disputes

March 27, 2019

Québec City, Canada, March 27, 2019 – Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval (CHU de Québec-UL) are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research. Université Laval and CHU de Québec-UL will share in the anticipated economic benefits associated with Intrarosa™.